---
figid: PMC7730176__ijms-21-09114-g003
figtitle: Estrogen and anti-estrogen signaling in glioblastoma
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- vectors
pmcid: PMC7730176
filename: ijms-21-09114-g003.jpg
figlink: pmc/articles/PMC7730176/figure/ijms-21-09114-f003/
number: F3
caption: Estrogen and anti-estrogen signaling in glioblastoma. Glioblastoma cells
  are sensitive to exogenous 17β-estradiol (E2) and 2-methoxyestradiol (2-ME) and
  the anti-estrogen tamoxifen (TAM) exposure through ERβ1, 2, 5 and ERα36 receptors
  that trigger non-genomic signaling. Tamoxifen-induced ERα36-dependent pathway involves
  PI3K-Akt and mTOR signaling to enhance autophagy and resistance to anti-cancer therapy.
  In the presence of 17β-estradiol or 2-methoxyestradiol, ERβ1 and ERβ5 nuclear receptors
  stimulate mTOR, JAK/STAT, NF-kB or JNK signaling to impact cancer cell proliferation,
  migration/invasion, survival or resistance to chemotherapy or may directly modulate
  the expression of their target genes. ERβ2 isoform is expressed in most glioblastoma
  cell lines or patient tumor samples but the downstream signaling remains to be determined.
  Endogenous production of estrogens by aromatase may be stimulated by an enhanced
  expression of the enzyme through vitamin D (VD), mifepristone (RU486) or dexamethasone
  (DEX) exposure, leading to increased tumor cell proliferation whereas the administration
  of letrozole (LET), a competitive inhibitor of aromatase activity, results in tumor
  volume reduction.
papertitle: 'Astrocytoma: A Hormone-Sensitive Tumor?.'
reftext: Alex Hirtz, et al. Int J Mol Sci. 2020 Dec;21(23):9114.
year: '2020'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9687912
figid_alias: PMC7730176__F3
figtype: Figure
organisms_ner:
- Homo sapiens
- Rattus norvegicus
redirect_from: /figures/PMC7730176__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC7730176__ijms-21-09114-g003.html
  '@type': Dataset
  description: Estrogen and anti-estrogen signaling in glioblastoma. Glioblastoma
    cells are sensitive to exogenous 17β-estradiol (E2) and 2-methoxyestradiol (2-ME)
    and the anti-estrogen tamoxifen (TAM) exposure through ERβ1, 2, 5 and ERα36 receptors
    that trigger non-genomic signaling. Tamoxifen-induced ERα36-dependent pathway
    involves PI3K-Akt and mTOR signaling to enhance autophagy and resistance to anti-cancer
    therapy. In the presence of 17β-estradiol or 2-methoxyestradiol, ERβ1 and ERβ5
    nuclear receptors stimulate mTOR, JAK/STAT, NF-kB or JNK signaling to impact cancer
    cell proliferation, migration/invasion, survival or resistance to chemotherapy
    or may directly modulate the expression of their target genes. ERβ2 isoform is
    expressed in most glioblastoma cell lines or patient tumor samples but the downstream
    signaling remains to be determined. Endogenous production of estrogens by aromatase
    may be stimulated by an enhanced expression of the enzyme through vitamin D (VD),
    mifepristone (RU486) or dexamethasone (DEX) exposure, leading to increased tumor
    cell proliferation whereas the administration of letrozole (LET), a competitive
    inhibitor of aromatase activity, results in tumor volume reduction.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - TAM
  - STIM1
  - ESR2
  - MTOR
  - NFKB1
  - MAPK8
  - MAPK9
  - MAPK10
  - AKT1
  - AKT2
  - AKT3
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - EIF4EBP1
  - STAT3
  - JUN
  - TF
  - Esr2
  - Cyp19a1
  - Mtor
  - Nfkb1
  - Mapk8
  - Akt1
  - Stat3
  - Jun
  - Tf
  - TAM
  - RU486
  - DEX
---
